SAMRAT PHARMACHEM LTD (530125) - STOCK OF THE WEEK

Dear Investor friends, Today I am expressing my opinion on  Chemical company.

SAMRAT PHARMACHEM LTD (530125)

Samrat Pharmachem Limited is an ISO 9000 Gujrat based company incorporated in1992.Its promoter is having vast experience in Pharmachem business. The Company is currently manufacturing Iodine salts & Bromine salts. The finished products produced by the Company are used in various industries like Pharmaceuticals, Chemicals, Food, Fertilizer, Salt etc.

Company became public in 1995, immediately after company has acquired more land adjacent to the original factory premises to cater the production demand. In 2006 Company has expanded its business by constructing the new manufacturing facility and in 2011 company has made its corporate office in Mumbai.  

PRODUCTS

The company has state of the art plant at Ankleshwar. The products of the Company are well received in Indian & Foreign markets. As mentioned earlier company produces products of Iodine derivatives which is having a huge demand in Pharma and Chemical sector.The Company's products include Calcium iodate monohydrate, Copper iodide, Hydriodic acid 47%, Iodine, Iodine monochloride, Iodoethane (Ethyl iodide), Potassium bromide, Potassium iodate, Potassium iodide, Potassium metaperiodate, Sodium iodide, Sodium iodate, Sodium metaperiodate, Hydriodic acid 57% and Trimethyl sulfoxoniumiodide.

 Following are the main products of the company.

Its plant and machinery includes centrifuges, tray driers, stirrers, vacuum pumps, chilling plant, shifter, electrolytic cells, electric lift, sewing machine, filtration unit, rectifiers, electrolytic cells and boilers.

Company is having its own Effluent treatment plant for the effluent treatment generated from the plant. It is having modern facilities to cater the stringent pollution norms.

PLEASE NOTE: THIS IS NOT A RESEARCH REPORT AND NOT ANY RECOMMENDATION REPORT.

Company website: Click here

FINANCIALS AND OUTLOOK

Company shares are trading in BSE.

Promoter holding: 48.32 % as on Dec qtr.

Company posted 25.08 Cr top line in Dec Qtr.

Net profit is 1.41 Cr bottom-line in Dec Qtr.

Operating Profits were improved from last Qtr.

Debt to equity ratio: 0.45

Stock is trading at Rs 149

Company is mainly engaged in the business manufacturing of Iodine and Bromine derivatives, which is having huge demand in pharma, chemical and food and fertiliser sectors. These products are falling in both consumption and chemical theme domain is having a huge growth potential in the future.

By considering above, and performance of the company over QOQ investors will get handsome returns in a days to come.

NOTE : THE ABOVE IS NOT A RESEARCH REPORT NOR A RECOMMENDATION  BUT INFORMATION AS AVAILABLE ON PUBLIC DOMAIN. 

Registration status with SEBI: I am not registered with SEBI under the (Research Analyst) regulations 2014 and as per clarifications provided by SEBI: “Any person who makes recommendation or offers an opinion concerning securities or public offers only through public media is not required to obtain registration as research analyst under RA Regulations”